A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TT-00973-MS Tablets in Patients With Advanced Solid Tumors
Latest Information Update: 13 Jan 2023
At a glance
- Drugs TT-00973-MS (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors TransThera Biosciences
Most Recent Events
- 13 Jan 2023 New trial record